Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in patients with resectable esophageal squamous cell carcinoma: a systematic review and meta-analysis.

ABSTRACT:

Background

Currently, there is a surge in clinical trials investigating neoadjuvant immunotherapy (NAI) and its combination with other treatments for resectable esophageal squamous cell carcinoma (ESCC). However, systematic evaluations of these studies are relatively scarce. This study aims to explore the latest evidence on the survival benefits of NAI combined with chemotherapy (NAIC) for patients with resectable ESCC.

Methods

Relevant literature was searched in PubMed, Embase, The Cochrane Library, and Web of Science databases up to July 16, 2024. Studies meeting the research criteria were selected. Endpoints included pathological complete response (pCR), major pathological response (MPR), surgery rate (SR), R0 resection rate, pathological downstaging rate (PDR), programme

SUBMITTER: Li CR 

PROVIDER: S-EPMC12268882 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature